Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

Fig. 3Fig. 3

Findings from the main analysis. A Odds of all-cause mortality with SGLT2i + GLP-1RA combination therapy versus SGLT2i or GLP-1RA therapy. B Changes in BMI with combination therapy at the baseline versus the 6-month follow-up. C Changes in SBP with combination therapy at the baseline versus the 6-month follow-up. D Changes in total cholesterol with combination therapy at the baseline versus the 6-month follow-up. E Changes in eGFR with simultaneous combination therapy at the baseline versus the 6-month follow-up. F Changes in HbA1c with combination therapy at the baseline versus the 6-month follow-up. G Changes in FPG with combination therapy at the baseline versus the 6-month follow-up. BMI Body mass index, CI confidence interval, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, M–H Mantel–Haenszel, GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin, IV importance value, SBP systolic blood pressure, SD standard deviation, SGLT2i Sodium–glucose transport protein 2 inhibitor

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840